Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS), a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at ₹484.95, representing a one-day gain of ₹33.60 or 7.44%.
Quarterly Results
Consolidated revenue for the quarter was ₹1,160 crore, representing a 14.8% increase over the ₹1,010 crore reported in the same period last year. Adjusted Profit After Tax (PAT) grew 29.5% year-on-year to ₹86 crore, while Adjusted EBITDA reached ₹147 crore with a margin of 12.7%. Segment revenue shares included CDMO at 79.0%, domestic branded formulations at 9.9%, and API at 4.7%. The company reported ₹18 crore in exceptional expenses and ₹34 crore in other income for the period.
Annual Performance Context
For the first nine months of FY26, consolidated total income reached ₹3,295 crore, a 6.4% increase over the ₹3,097 crore reported in the prior year. Nine-month revenue stood at ₹3,201 crore with an adjusted EBITDA of ₹370 crore, representing a 1.0% growth. Adjusted PAT for the nine-month period was ₹193 crore, a 1.6% increase compared to ₹190 crore in the previous year. Margins for the nine-month period were 11.6% for adjusted EBITDA and 5.9% for adjusted PAT.
Business and Operations Update
The CDMO segment achieved double-digit volume growth despite a 1.2% growth rate in the broader Indian Pharmaceutical Market, while international branded formulation exports more than doubled on a sequential basis. API pricing remained under pressure, though the company noted “initial signs of stabilization” in select molecules and reported overall capacity utilization of 47%. Revenue growth was driven by the CDMO and international formulation segments, while the company continued to consolidate its trade generics business. The company received EU GMP certification for its oral solids and oral liquids facilities and its first UK MHRA approval for Rivaroxaban tablets. Sandeep Jain stated, “The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams”.
Forward Outlook
The company plans to begin supplies from its European CDMO project in FY 28. Commercial supplies for the Zambia project from Indian facilities are expected to begin in the first half of FY27. Sanjeev Jain stated the company remains “focused on our long-term growth drivers that include innovation, operational efficiency, cost controls and strategic partnerships”. Company issued no further specific financial guidance.
Performance Summary
The company reported ₹1,160 crore in quarterly revenue, led by volume growth in the CDMO vertical. Profitability improved year-on-year with adjusted PAT reaching ₹86 crore despite ongoing pricing pressure in the API segment. The company advanced its global regulatory standing with certifications from the European Union and the United Kingdom. Overall capacity utilization reached 47% as newer facilities continued to ramp up.